Lead Cap Use in Interventional Cardiology: Time to Protect Our Head in the Cardiac Catheterisation Laboratory? [0.03%]
介入性心脏病学中头部铅防护罩的使用：是时候在心脏导管实验室保护我们的头部了吗？
Yasar Sattar,Prasanna M Sengodan,Mustafa Sajjad Cheema et al.
Yasar Sattar et al.
Background: Radiation exposure is an occupational hazard for interventional cardiologists and cardiac catheterisation laboratory staff that can manifest with serious long-term health consequences. Personal protective equipment, including le...
Clinical and Radiographic Predictors of Successful Coronary Angiography Through Right Radial Artery Access [0.03%]
经右桡动脉入路冠状动脉造影成功的影响因素分析
Sohil Elfar,Ahmed Onsy,Mohamed Amr Farouk
Sohil Elfar
Background: One of the limitations of the right radial access approach is complex vessel anatomy, such as subclavian tortuosity. Several clinical predictors have been proposed for tortuosities, such as older age, female sex and hypertension...
Is It Really Safe to Discontinue Antiplatelet Therapy 12 Months After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation? [0.03%]
房颤患者冠脉介入术后一年就停用抗血小板药物安全吗？
Balen Abdulrahman,Richard J Jabbour,Nick Curzen
Balen Abdulrahman
The prevalence of AF in patients with coronary artery disease is high. The guidelines from many professional groups, including the European Society of Cardiology, American College of Cardiology/American Heart Association and Heart Rhythm So...
Contemporary Left Main Percutaneous Coronary Intervention: A State-of-the-art Review [0.03%]
当代左主干经皮冠状动脉介入治疗进展及专家共识解析
Refai Showkathali,Radha Priya Yalamanchi
Refai Showkathali
The majority of the left ventricular myocardium is supplied by the left main coronary artery. Atherosclerotic obstruction of the left main coronary artery therefore leads to significant myocardial jeopardy. Coronary artery bypass surgery (C...
Severe Acute Thrombocytopenia After Treatment with Tirofiban: A Case Series Approach [0.03%]
替罗非班治疗后严重急性血小板减少症的病例系列分析
Gian-Manuel Jiménez-Rodríguez,Patricia Carmona-Levario,José-Alberto Ayón-Martínez et al.
Gian-Manuel Jiménez-Rodríguez et al.
Glycoprotein IIb/IIIa inhibitors are an adjuvant therapy for the treatment of patients with acute coronary syndromes. The main adverse reactions are bleeding and thrombocytopenia in 1-2% of cases. A 66-year-old woman arrived at the emergenc...
Myval: A Novel Transcatheter Heart Valve for the Treatment of Severe Aortic Stenosis [0.03%]
Myval：用于治疗严重主动脉瓣狭窄的新型经导管心脏瓣膜
Ashok Seth,Vijay Kumar,Vivudh Pratap Singh et al.
Ashok Seth et al.
Transcatheter aortic valve implantation (TAVI) performed using femoral arterial access is now a guideline recommended treatment for severe calcific aortic stenosis (AS) in elderly patients. Technological advancements and procedural refineme...
Johny Nicolas,Nicholas L Pitaro,Birgit Vogel et al.
Johny Nicolas et al.
Maja Rojko,Natasa Cernic Suligoj,Metka Zorc et al.
Maja Rojko et al.
Background: COVID-19 infection has been associated with paradoxical thromboembolism through a patent foramen ovale (PFO) and ischaemic stroke. Such events have not been reported after COVID-19 vaccination. The aim of the present study was t...
Long-term Outcomes for Drug-eluting Balloons versus Drug-eluting Stents in the Treatment of Small Vessel Coronary Artery Disease: A Systematic Review and Meta-analysis [0.03%]
药物洗脱球囊与药物洗脱支架治疗小血管冠心病长期疗效的系统评价和 meta 分析
Greg Murphy,Ailish Naughton,Rory Durand et al.
Greg Murphy et al.
Background: This systematic review and meta-analysis compares long-term outcomes follow-up data comparing drug-eluting balloons (DEBs) and drug-eluting stents (DESs) in interventional treatment of small coronary artery disease (
Sudden Cardiac Death in Ischaemic Cardiomyopathy and the Primary Prevention ICD: Time for a More a Personalised Approach? [0.03%]
缺血性心肌病和用于主要预防的植入型心脏除颤器：是时候采取更个性化的治疗方法了吗？
Saad M Ezad,Girish Babu,Peter O&#x;Kane
Saad M Ezad
Guidelines recommend primary prevention implantable cardioverter defibrillator (PPICD) for left ventricular ejection fraction (LVEF)